Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | NAMPT | P43490 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959162 | 0.95 | HDAC1 (0.61) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL4457324 | 0.92 | KMT2A (0.51) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL3013545 | 0.92 | KMT2A (0.51) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| Dimethylformamide SCHEMBL28335949 | 0.90 | NR1H4 (0.50) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL3180689 | 0.90 | L3MBTL1 (0.61) | NAMPTHDAC1L3MBTL1MAPTGAA | |
| SCHEMBL24891652 | 0.89 | NAMPT (0.66) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL8203403 | 0.88 | NAMPT (0.54) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL2874913 | 0.88 | NAMPT (0.54) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL10165179 | 0.87 | NAMPT (0.56) | KMT2ANR1H4EPHX2NAMPTHDAC1 | |
| SCHEMBL8127981 | 0.87 | EPHX2 (0.59) | KMT2ANR1H4EPHX2NAMPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1064 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144069-A1 | BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-05-08 | — | — | US | claimed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20260001904-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORP (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4954512-A | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1990-09-04 | — | — | US | disclosed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | disclosed |
| US-4895842-A | Phenylalanine derivative and proteinase inhibitor | SHOSUKE OKAMOTO (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4873253-A | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-10-10 | — | — | US | disclosed |
| EP-0186817-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTI-ALLERGIC AGENT CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0317959-A2 | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1989-05-31 | — | — | EP | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
| EP-0217286-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1987-04-08 | — | — | EP | disclosed |
| EP-0186817-A1 | 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1986-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885NR1H4 367/4885EPHX2 2207/4885 |
| US-20260001904-A1 | COMPOUNDS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLR2E, NSUN2 | KMT2A 2280/4885NR1H4 453/4885EPHX2 1757/4885 |
| US-20250144069-A1 | BILOBALIDE DERIVATIVE COMPOUNDS FOR TREATING NEUROLOGICAL DISEASES AND CANCERS | BTD, BCHE, BRCA1 | KMT2A 1707/4885NR1H4 2968/4885EPHX2 1019/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | KMT2A 1674/4885NR1H4 438/4885EPHX2 1391/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | KMT2A 1971/4885NR1H4 1856/4885EPHX2 316/4885 |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | SLC6A4, HTR4, HTR1A | KMT2A 189/4885NR1H4 695/4885EPHX2 2116/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | KMT2A 1987/4885NR1H4 491/4885EPHX2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.